SCHEMBL4674849

SCHEMBL4674849

O=C(O)C(O)=CC(=O)c1c[nH]c(S(=O)(=O)c2ccc(F)cc2)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.38
AKR1C3 P42330 2/20 0.38
AKR1C2 P52895 1/20 0.38
AKR1C1 Q04828 1/20 0.38
EPHX2 P34913 1/20 0.34
KDM4E B2RXH2 2/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
BRAF P15056 1/20 0.33
HSD11B1 P28845 1/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
PTGS1 P23219 1/20 0.33
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674846 1.00 PTGS2 (0.38) PTGS2AKR1C3AKR1C2AKR1C1EPHX2
SCHEMBL4675646 0.88 GAA (0.36) PTGS2AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL4675643 0.88 GAA (0.36) PTGS2AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL4674131 0.87 AKR1C3 (0.38) AKR1C3AKR1C2AKR1C1KDM4EMAPT
SCHEMBL4674129 0.87 AKR1C3 (0.38) AKR1C3AKR1C2AKR1C1KDM4EMAPT
SCHEMBL4671347 0.78 MAPT (0.38) PTGS2AKR1C3AKR1C2AKR1C1MAPT
SCHEMBL4671350 0.78 MAPT (0.38) PTGS2AKR1C3AKR1C2AKR1C1MAPT
SCHEMBL4670742 0.76 PTGS2 (0.36) PTGS2AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL4670745 0.76 PTGS2 (0.36) PTGS2AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL4672596 0.74 PTGS2 (0.38) PTGS2AKR1C3AKR1C2AKR1C1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PTGS2 4586/4885AKR1C3 30/4885AKR1C2 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.